Amylyx Pharmaceuticals, Inc. (AMLX) has 12 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 6 sales totalling $3.5M. Most recent filing: Sept. 14, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 14, 2026 filed Sept. 10, 2026 | Bedrosian Camille L Chief Medical Officer | −$324,868 | 10,028 | −3% | No | |
|
|
||||||
| Sept. 14, 2026 filed Sept. 10, 2026 | Klee Justin B. Co-Chief Executive Officer | −$980,263 | 30,464 | −1% | No | |
|
|
||||||
| Sept. 14, 2026 filed Sept. 10, 2026 | Cohen Joshua B Co-Chief Executive Officer | −$980,504 | 30,464 | −1% | No | |
|
|
||||||
| Sept. 14, 2026 filed Sept. 10, 2026 | Mazzariello Gina Chief Legal Officer | −$309,506 | 9,536 | −5% | No | |
|
|
||||||
| Sept. 14, 2026 filed Sept. 10, 2026 | FRATES JAMES M Chief Financial Officer | −$349,821 | 10,810 | −4% | No | |
|
|
||||||
Showing the 5 most recent of 12 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free